Chronic nicotine exposure during adolescence differentially influences calcium-binding proteins in rat anterior cingulate cortex.
We have recently shown that chronic amphetamine exposure selectively up-regulates parvalbumin (PV) calcium-binding proteins in the anterior cingulate cortex (ACC). In this study, we evaluated the effects of chronic nicotine (NIC) exposure on PV, calbindin D28k (CB) and calretinin (CR) calcium-binding protein immunostaining in ACC GABAergic interneurons. Chronic NIC exposure for 3 weeks in adolescent rats, either via drinking water (the oral group) or by twice daily subcutaneous injections (the injection group), resulted in the expression of high levels of CR proteins in the ACC but not in the parietal cortex. Larger increases in the density of CR-immunoreactive (ir) neurons were noted in the NIC-injected rats at 0-day withdrawal (45% increase) compared with the oral group (26% increase). The larger increases in CR-ir neuron density in the NIC-injected rats were also reflected by prominent CR-ir processes across cortical layers. The density of PV-ir neurons was also increased (37%) at 0-day withdrawal but only in the oral NIC group and no changes in CB-ir neuron density were observed in either NIC group. Combined dual-immunofluorescence and confocal microscopy revealed that somatodendritic alpha4 nicotinic acetylcholine receptors colocalized with cortical neurons stained positively for CR, PV or CB. These results suggest that CR- and/or PV-ir-containing GABA interneurons may be involved in channeling the effects of NIC in the ACC, which is closely associated with the ventral basal ganglia circuit that is linked to brain reward function.
Liu
Jen-Jane
JJ
Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, USA.
Mohila
Carrie A
CA
Gong
Yuna
Y
Govindarajan
Nalini
N
Onn
Shao-Pii
SP
D000284:Administration, Oral; D000375:Aging / Q000502:physiology; D000818:Animals; D002135:Calcium-Binding Proteins / Q000096:biosynthesis*; D005455:Fluorescent Antibody Technique; D006179:Gyrus Cinguli / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D007395:Interneurons / Q000502:physiology; D008297:Male; D018613:Microscopy, Confocal; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D010296:Parietal Lobe / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D002135:Calcium-Binding Proteins; D018722:Nicotinic Agonists; D005680:gamma-Aminobutyric Acid; D009538:Nicotine